South Korea plans hospital-only abortion pills up to nine weeks by early 2027

South Korea's government said on 16 September that it will introduce abortion pills for pregnancies of up to nine weeks, with a target of the first quarter of 2027 if the drug reviews finish on time. The announcement came at a policy coordination meeting and was presented by the ministries of gender equality, health and food and drug safety. Prime Minister Han Seong-sook said some women were already using dangerous methods and that leaving the gap unattended amounted to neglecting lives.

The Constitutional Court struck down the criminal ban in 2019. The National Assembly never wrote a replacement statute. Clinics have lived in that vacuum. Medication abortion has not been a licensed product. The Lee Jae Myung government listed the pills as an administrative task and, in July, told ministries to find a way to make them available even before a full legal rewrite.

How the first two years would work

The roll-out is phased. For the first two years, prescription and dispensing would happen only inside hospitals and clinics. Gender Equality Minister Won Min-kyong said the government would watch that period for safety problems and side effects. After that, the plan is to move toward doctor prescriptions with pharmacy dispensing. The nine-week, or 63-day, cutoff is written into the first licences under review.

The Ministry of Food and Drug Safety has applications in hand. One product under review is Mifegymiso, also referred to in briefings as Mifegyne, filed by Hyundai Pharm, for use within 63 days of conception. A ministry official said the aim was the first quarter of next year if the safety and quality checks are completed. That is a condition, not a date carved in law.

What the vacuum has already done

Without a licensed pill, women who want a medical abortion have used informal channels or surgical procedures that depend on the willingness of individual doctors. The Court ruling removed the crime. It did not build a protocol. The government's argument is that a hospital-only product is safer than the present market and faster than waiting for the Assembly. Critics of abortion will treat the circular as a bypass of parliament. Supporters will treat the two-year clinic lock as too tight. Both readings can be true at once.

The practical test is whether Hyundai Pharm's file, and any rival file, clears the food and drug ministry before March 2027, and whether hospitals then stock the product rather than sit on the licence. A pill that exists only on a circular is still a vacuum. A pill that sits in a hospital cabinet by next spring is a different fact.